Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
Organoselenium compound for treating cancer
US12478595B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-12478595-B1 |
| Application number | US-202418954406-A |
| Country | US |
| Kind code | B1 |
| Filing date | Nov 20, 2024 |
| Priority date | Nov 20, 2024 |
| Publication date | Nov 25, 2025 |
| Grant date | Nov 25, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating includes contacting cancer cells with a bis-(organoselanyl urea)aryl agent of Formula (I). The method includes effective inhibition of growth of cancer cells using the bis-(organoselanyl urea)aryl agent of Formula (I) as compared to doxorubicin
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method of in vitro inhibition of a cancer cell line, the method comprising: contacting cells of the cancer cell line with 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea wherein the cancer is a cancer cell line is selected from the group consisting of HN9, HuH7, FaDu, MCF7, HEPG2, A549, HCT116, and A375. 2 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has a cancer cell growth inhibition percentage of at least 65%. 3 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has a non-cancer cell growth inhibition percentage of 55% or less against a non-cancer cell line. 4 . The method of claim 3 , wherein the non-cancer cell line is a normal oral epithelial cell line or a human skin fibroblast normal cell line. 5 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has a cancer cell growth inhibition percentage of at least 74%. 6 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has a non-cancer cell growth inhibition percentage of 35% or less against a non-cancer cell line. 7 . The method of claim 6 , wherein the non-cancer cell line is a normal oral epithelial cell line or a human skin fibroblast normal cell line. 8 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has a cancer cell growth inhibition percentage at least 10% greater than a cancer cell growth inhibition percentage of doxorubicin. 9 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has a cancer cell growth inhibition percentage at least 15% greater than a cancer cell growth inhibition percentage of doxorubicin. 10 . The method of claim 1 , wherein the 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl) ureido)cyclohexyl)methyl)urea has having a cancer cell growth inhibition percentage at least 30% greater than a cancer cell growth inhibition percentage of doxorubicin.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12478595B1 cover?
- A method of treating includes contacting cancer cells with a bis-(organoselanyl urea)aryl agent of Formula (I). The method includes effective inhibition of growth of cancer cells using the bis-(organoselanyl urea)aryl agent of Formula (I) as compared to doxorubicin
- Who is the assignee on this patent?
- Imam Mohammad Ibn Saud Islamic Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/17. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).